NEW YORK, NY / ACCESSWIRE / September 25, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Vaxart, Inc. (NASDAQ:VXRT)
CONTACT JAKUBOWITZ ABOUT VXRT:
https://claimyourloss.com/securities/vaxart-inc-loss-submission-form/?id=9624&from=1
Class Period: June 25, 2020 - July 25, 2020
Lead Plaintiff Deadline: October 23, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) Vaxart exaggerated the prospects of its COVID-19 vaccine candidate, including its purported role or involvement in Operation Warp Speed ('OWS'), a program which commits the federal government to massive funding for the development of COVID-19 vaccines; 2) Vaxart's COVID-19 vaccine candidate had no reasonable prospect for mass production and marketing and was not among the companies chosen to receive significant financial support from OWS to produce hundreds of millions of vaccine doses; and 3) Vaxart's COVID-19 vaccine candidate was merely selected to participate in preliminary U.S. government studies to determine potential areas for possible OWS partnership and support.
Anaplan Inc. (NYSE:PLAN)
CONTACT JAKUBOWITZ ABOUT PLAN:
https://claimyourloss.com/securities/anaplan-inc-loss-submission-form/?id=9624&from=1
Class Period : November 21, 2019 - February 26, 2020
Lead Plaintiff Deadline: October 23, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was undergoing sales organization and execution challenges; (2) these organizational challenges were causing the Company to miss on closing very important large deals; and (3) as a result, Anaplan's financial guidance for "calculated billings growth" was baseless and unattainable. Further, while in possession of this material non-public information, Anaplan insiders dumped approximately $30 million worth of Anaplan stock at artificially inflated prices.
Odonate Therapeutics, Inc. (NASDAQ:ODT)
CONTACT JAKUBOWITZ ABOUT ODT:
https://claimyourloss.com/securities/odonate-therapeutics-inc-loss-submission-form/?id=9624&from=1
Class Period : December 7, 2017 - April 21, 2020
Lead Plaintiff Deadline: November 16, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law